Hence, to study the potential interplay between let-7 and RRM2 and to further explore the opportunity of utilizing let-7 for pancreatic cancer therapeutics, we sought to determine the direct impact of the human let-7 family on RRM2-mediated inherent gemcitabine resistance. This evidence concerns the gene RRM2 and familial pancreatic carcinoma.